Insmed reported $75.58M in Selling and Administration Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
DBV Technologies DBVT:US USD 3.05M 2.23M
Acelrx Pharmaceuticals ACRX:US USD 5.26M 1.56M
Alimera Sciences ALIM:US USD 9.86M 46K
Biomarin Pharmaceutical BMRN:US USD 216.82M 19.98M
Cytokinetics CYTK:US USD 48.22M 5.51M
Dynavax Technologies DVAX:US USD 32.04M 3.69M
Gilead Sciences GILD:US USD 1.21B 144M
Heron Therapeutics HRTX:US USD 28.18M 3.94M
Insmed INSM:US USD 75.58M 15.61M
Mirati Therapeutics MRTX:US USD 60.8M 6.57M
Novartis NVS:US USD 3.4B 185M
Ophthotech OPHT:US USD 17.54M 1.44M
Regeneron Pharmaceuticals REGN:US USD 529.1M 52.8M
Sarepta Therapeutics SRPT:US USD 104.79M 49.53M
Seattle Genetics SGEN:US USD 210.38M 9.88M
Ultragenyx Pharmaceutical RARE:US USD 69.84M 1.7M
Vertex Pharmaceuticals VRTX:US USD 246.8M 31.5M